Multivariate comparison of B-ultrasound guided and laparoscopic continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites

Abstract

B-ultrasound-guided and laparoscopy-assisted CHIPC have similar clinical efficacy for improving QOL and prolonging patient survival. B-ultrasound-guided CHIPC may, however, shorten operation times and reduce hospitalization costs, making the treatment available to a broader patient population, although port hole metastasis remains an issue.

Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification

“…In this regard, previous studies were mostly focused on searching for the optimal chemotherapy regimens against MA, including the paclitaxel with tegafur regimen, the combined intraperitoneal recombinant human endostatin and chemotherapy regimen, the catumaxomab regimen, the cediranib regimen, immunotherapy, and others. [29][30][31][32][33][34][35][36] However, the rate of complete remission with these regimens remains less than 30%.…”

Bladder intracavitary hyperthermic perfusion chemotherapy for the prevention of recurrence of non-muscle invasive bladder cancer after transurethral resection

“…According to our previous experience 3 rounds of HIPEC was used to treat abdominal tumors in order to get good outcomes (22)(23)(24)(25), consequently, BHPC was also conducted for 3 rounds in the present study. Nevertheless, for our self-developed device-based BHPC, the chemotherapeutic types of drugs and dosages involved, the treatment time and temperature are still being explored.…”

“…We developed a 'BR-TRG-I type high-precision hyperthermic intraperitoneal perfusion treatment system', which allows precise automatic control of the temperature and perfusion rate of the drug solution. This system includes an automatic cooling function and adaptive fuzzy control technology for precise control of the perfusion temperature and rate, and thus, control of the local temperature in the bladder cavity of NMIBC patients (22)(23)(24)(25). To effectively kill the residual cancer cells within the bladder as well as to kill the cancer cells dropped from the bladder cavity and adhered to the bladder wall, BHPC using this device was performed immediately after the TUR of bladder tumors instead of weeks later.…”

“…BHPC was performed using our novel 'BR-TRG-I type high-precision hyperthermic intraperitoneal perfusion treatment system' (Guangzhou Bright Medical Technology Co., Ltd. Guangzhou, China), in which adaptive fuzzy control technology is principally used for precise control of the drug solution perfusion temperature (±0.10̊C) and rate (±5%) (23)(24)(25)(26). The device, shown in Fig.…”

“…In addition, the pharmacokinetics of chemotherapeutic agents during thermochemotherapy is also not well understood. Over the past 6 years, we performed continuous circulatory hyperthermic intraperitoneal perfusion chemotherapy for malignant ascites using a novel 'BR-TRG-I type high-precision hyperthermic intraperitoneal perfusion treatment system' which can precisely maintain the temperature and perfusion rate of the drug solution, with satisfactory outcomes (22)(23)(24)(25). However, conductive BHPC for bladder cancer has been rarely reported.…”